Regeneron Genetics Center Partners with Olink to Analyze 200,000 Patient Samples for Proteomics Study

Regeneron Genetics Center has selected the Olink Explore HT proteomics platform for a large-scale study involving 200,000 patient samples from the Geisinger Health Study. The study aims to uncover new insights into human disease mechanisms and validate genetic hypotheses. The Olink Explore HT was chosen for its scalability, high throughput, and specificity, paving the way for future proteomics studies.

Regeneron Genetics Center (RGC) has announced the selection of the Olink Explore HT proteomics platform for a significant study involving nearly 200,000 patient samples from the Geisinger Health Study. The aim of this large-scale proteomics investigation is to unlock new insights into the dynamic biology and mechanisms of human disease, as well as to validate genetic hypotheses and solidify drug targets identified through RGC's genomic sequencing operations [1].

The Geisinger Health Study, characterized by its deep phenotyping data, offers a unique opportunity to monitor proteomic changes at scale. RGC's established infrastructure is designed to manage large-scale projects efficiently, making it well-suited for this ambitious endeavor. The choice of the Olink Explore HT platform follows its successful deployment in the UK Biobank Pharma Proteomics Project (UKB-PPP), the world’s largest human proteomics study [2].

Olink Explore HT was chosen for its unparalleled scalability, high throughput, and superior specificity, all of which are essential for processing such a vast number of samples. Carl Raimond, president of proteomic sciences at Thermo Fisher Scientific, expressed enthusiasm about the partnership, noting that the selection of Olink Explore HT underscores its ability to deliver robust and reliable data at scale. This project is expected to accelerate biomarker discovery and contribute significantly to the advancement of precision medicine [1].

John Overton, Vice President at Regeneron Genetics Center, highlighted the platform's value in their pursuit of deeper biological understanding. He noted that its scalability and specificity are crucial for handling the complexities of a project of this size, and that the study is anticipated to yield transformative insights that will drive innovation in scientific discoveries [1].

The comprehensive mapping of protein levels across such a large population of patient samples represents a significant milestone in the field of proteomics. This endeavor paves the way for future studies to advance our understanding of human health and disease [1].

References:

[1] https://www.biospace.com/press-releases/regeneron-genetics-center-selects-olink-explore-ht-for-landmark-proteomics-study-of-200-000-patient-samples
[2] https://finance.yahoo.com/news/regeneron-genetics-center-selects-olink-121500767.html